Evidence map›Paper›PMID 42129168›Full record

Trial reportNature communications2026

Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trial.

Ana C Veneziani, Stephanie Lheureux, Douglas G Millar, Neesha Dhani, Ilaria Colombo, Ainhoa Madariaga, Pamela Soberanis Pina, Swati Atale, Yin-Ling Chan, Joshua Lee and 8 more

Registry-linked trialAbstract readClinical Trial, Phase IIClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03029403 (A Phase 2 Study of Pembrolizumab), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03029403 phase2active not recruitingnot on this map

A Phase 2 Study of Pembrolizumab (MK-3475), DPX-Survivac Vaccine and Low Dose of Cyclophosphamide Combination in Patients With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

TypeinterventionalSponsorUniversity Health Network, TorontoRan2018 to 2026Enrolled47ConditionsAdvanced Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube CancerArmsPembrolizumab, DPX-Survivac, Cyclophosphamide
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ana C VenezianiDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-3980-034X
Stephanie LheureuxDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Douglas G MillarTumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-8640-7148
Neesha DhaniDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Ilaria ColomboOncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-0602-8667
Ainhoa MadariagaDepartment of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain.ORCID http://orcid.org/0000-0001-7166-9762
Pamela Soberanis PinaShirley and Jim Fielding Northeast Cancer Centre, Health Sciences North, Sudbury, Canada.
Swati AtaleDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Yin-Ling ChanDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Joshua LeeDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Janelle RamsahaiDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Judy QuintosDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Lisa WangDepartment of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain.
Xuan LiDepartment of Biostatistics, Princess Margaret Hospital Cancer Centre, Toronto, ON, Canada.
Valerie BoweringDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Pam OhashiTumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Ben WangTumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Amit M OzaDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. amit.oza@uhn.ca.ORCID http://orcid.org/0000-0002-9510-8641

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This investigator-initiated, open-label phase 1/2 clinical trial evaluates maveropepimut-S, a survivin-targeting vaccine, combined with pembrolizumab and low-dose cyclophosphamide in patients with recurrent epithelial ovarian cancer (ClinicalTrials.gov identifier: NCT03029403). The primary endpoints are safety and clinical efficacy measured by overall response rate and disease control rate. Secondary endpoints include recommended phase 2 dose, progression-free survival, overall survival, and survivin-specific immune response. Forty-seven patients are enrolled and forty-four are evaluable. Most treatment-related adverse events are grade 1 or 2, most commonly injection site reactions. The recommended phase 2 dose is 0.25 milliliters. The overall response rate is 23% and the disease control rate is 67%, with greater activity in platinum-sensitive disease. Median progression-free survival is 6.3 months in platinum-sensitive disease and 1.2 months in platinum-resistant disease. Survivin-specific immune responses occur in 62.5% of tested patients and correlate with clinical benefit. The combination demonstrates tolerability and sustained clinical activity.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCancer VaccinesCarcinoma, Ovarian EpithelialCyclophosphamideOvarian NeoplasmsAdultAgedFemaleHumansMiddle AgedNeoplasm MetastasisProgression-Free SurvivalSurvivinAntibodies, Monoclonal, HumanizedBIRC5 protein, humanCancer VaccinesCyclophosphamidepembrolizumabSurvivin

Identifiers

PMID42129168
PMCPMC13377177

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.